NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

製藥產業的交易與趨勢(2021年3月):聯盟,授權,投資,合併,收購(M&A)

Pharmaceuticals Industry Deals and Trends in March 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

出版商 GlobalData 商品編碼 1014030
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
製藥產業的交易與趨勢(2021年3月):聯盟,授權,投資,合併,收購(M&A) Pharmaceuticals Industry Deals and Trends in March 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
出版日期: 2021年06月15日內容資訊: 英文 86 Pages
簡介

本報告提供製藥產業的交易與趨勢的相關調查,聯盟及授權交易,M&A,股票/債務公開,非上市股票,合資經營財務相關詳細資訊,過去的交易數銷售額比較資料,各交易類型、治療領域、地區的分析,製藥產業的主要財務諮詢企業相關資訊。

目錄

第1章 目錄

  • 表格的清單
  • 圖的清單

第2章 全球製藥、醫療保健:交易概要

  • 全球製藥、醫療保健:交易分析(2021年3月)
  • 全球製藥、醫療保健:主要交易(2021年3月)
  • 全球製藥、醫療保健:各類型,交易數(2021年3月)
  • 全球製藥、醫療保健:各類型,交易額(2021年3月)

第3章 全球製藥、醫療保健:交易,摘要,各類型

  • 全球製藥、醫療保健:M&A(2021年3月)
  • 全球製藥、醫療保健:股票公開(2021年3月)
  • 全球製藥、醫療保健:非上市股票、創業投資(2021年3月)
  • 全球製藥、醫療保健:聯盟交易(2021年3月)
  • 全球製藥、醫療保健:各治療領域聯盟交易(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各聯盟交易,簽約金及階段性付款,各交易金額(2021年3月)
  • 全球製藥、醫療保健:各治療領域聯盟交易,簽約金及階段性付款,各交易金額(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各階段聯盟交易,交易數(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各階段聯盟交易,交易額(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各階段聯盟交易,簽約金及階段性付款,各交易金額(2020年10月∼2021年3月)

第4章 全球製藥、醫療保健:授權契約(2021年3月)

  • 全球製藥、醫療保健:授權合約(2021年3月)
  • 全球製藥、醫療保健:授權合約交易,簽約金及階段性付款,交易額(2021年3月)
  • 全球製藥、醫療保健:各治療領域授權合約交易,交易總額(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各治療領域授權合約交易,簽約金及階段性付款(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各階段授權合約交易,總交易額(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:各階段授權合約交易,簽約金及階段性付款(2020年10月∼2021年3月)

第5章 全球醫藥品和醫療保健:各治療領域的交易概要

  • 全球製藥、醫療保健:腫瘤(2021年3月)
  • 全球製藥、醫療保健:中樞神經(2021年3月)
  • 全球製藥、醫療保健:感染疾病(2021年3月)
  • 全球製藥、醫療保健:心臟血管(2021年3月)
  • 全球製藥、醫療保健:免疫(2021年3月)
  • 全球製藥、醫療保健:代謝性疾病(2021年3月)
  • 全球製藥、醫療保健:消化器官系統疾病(2021年3月)

第6章 地區交易概要

  • 製藥、醫療保健:北美(2021年3月)
  • 製藥、醫療保健:歐洲(2021年3月)
  • 製藥、醫療保健:亞太地區(2021年3月)
  • 製藥、醫療保健:其他地區(2021年3月)

第7章 全球製藥及醫療保健:主要金融顧問

  • 全球製藥、醫療保健:主要金融顧問,M&A(2020年10月∼2021年3月)
  • 全球製藥、醫療保健:主要金融顧問,股票公開(2020年10月∼2021年3月)

第8章 詳細資訊

  • 調查手法
  • 關於GlobalData
  • 諮詢方式
  • 資訊披露
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC0577MD

GlobalData's "Pharmaceuticals Industry Deals and Trends in March 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market.
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pharmaceuticals & Healthcare, Global, Deal Summary

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2021
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2021
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2021
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2021

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2021
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2021
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2021
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2021
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2020- March 2021
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2020- March 2021
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2020- March 2021
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2021
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2021
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2020- March 2021
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2020- March 2021
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2020- March 2021

5 & Healthcare, Global, Deal Summary by Therapy Area

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2021
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2021
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2021
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2021
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2021
  • 5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, March 2021
  • 5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, March 2021

6 Deal Summary by Geography

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, March 2021
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2021
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, March 2021
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2021

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2020- March 2021
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2020- March 2021

8 Further Information

  • 8.1 Methodology
  • 8.2 About GlobalData
  • 8.3 Contact Us
  • 8.4 Disclosure information
  • 8.5 Disclaimer

List of Tables

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2021
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2021
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2021
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2021
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2021
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2020- March 2021
  • Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2021
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2020- March 2021
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2021
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2020- March 2021
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2021
  • Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2020- March 2021
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2021
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2021
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2021
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021

List of Figures

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), March 2021
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2021
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2020- March 2021
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), March 2021
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2021
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2020- March 2021
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2020- March 2021
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, October 2020- March 2021
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2020- March 2021
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2021
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2020- March 2021
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2020- March 2021